Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer (NEOTRIO-HR)
Neoadjuvant Toripalimab and Radiotherapy Treatment in Lymph Nodes Positive HR Positve Breast Cancer（NEOTRIO-HR）
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
This PHASE2 trial investigates Breast Adenocarcinoma and is currently actively recruiting participants. Second Affiliated Hospital, School of Medicine, Zhejiang University leads this study, which shows 3 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
3 versions recorded-
Mar 2025 — Present [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2025 — Mar 2025 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2024 — Jan 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Second Affiliated Hospital, School of Medicine, Zhejiang University
For direct contact, visit the study record on ClinicalTrials.gov .